MedTrace Logo

Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.

NCT04131322 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-01-12

No results posted yet for this study

Summary

Loss of response of the Adalimumab biosimilar compared with the original drug.

Conditions

Interventions

DRUG

Amgevita 40Mg Solution for Injection

Adalimumab 40Mg Solution for Injection

DRUG

HUMIRA 40Mg Solution for Injection

Adalimumab 40Mg Solution for Injection

Sponsors & Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Federico Argüelles Arias, Md PhD · Universitary Hospital Virgen Macarena

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2020-06-08
Completion
2020-06-08

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131322 on ClinicalTrials.gov